Mark X Sliwkowski
Overview
Explore the profile of Mark X Sliwkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
6993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewis G, Li G, Guo J, Yu S, Fields C, Lee G, et al.
Nat Commun
. 2024 Jan;
15(1):466.
PMID: 38212321
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab...
2.
Li G, Guo J, Shen B, Bumbaca Yadav D, Sliwkowski M, Crocker L, et al.
Mol Cancer Ther
. 2018 Apr;
17(7):1441-1453.
PMID: 29695635
The receptor tyrosine kinase HER2 is overexpressed in approximately 20% of breast cancer, and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla, T-DM1), an antibody-drug conjugate that is...
3.
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates
Caculitan N, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak K, Liu Y, et al.
Cancer Res
. 2017 Oct;
77(24):7027-7037.
PMID: 29046337
Antibody-drug conjugates (ADC) are designed to selectively bind to tumor antigens via the antibody and release their cytotoxic payload upon internalization. Controllable payload release through judicious design of the linker...
4.
Chung I, Reichelt M, Shao L, Akita R, Koeppen H, Rangell L, et al.
Nat Commun
. 2016 Sep;
7:12742.
PMID: 27599456
Breast cancers (BC) with HER2 overexpression (referred to as HER2 positive) progress more aggressively than those with normal expression. Targeted therapies against HER2 can successfully delay the progression of HER2-positive...
5.
Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, et al.
Cancer Immunol Res
. 2016 Jun;
4(8):688-97.
PMID: 27241844
The development of targeted therapies that affect multiple signaling pathways and stimulate antitumor immunity is greatly needed. About 20% of patients with breast cancer overexpress HER2. Small molecules and antibodies...
6.
Li C, Huang S, Armstrong E, Francis D, Werner L, Sliwkowski M, et al.
Mol Cancer Ther
. 2015 Jul;
14(9):2049-59.
PMID: 26141946
Human epidermal growth factor receptor family members (EGFR, HER2, HER3, and HER4) play important roles in tumorigenesis and response to cancer therapeutics. In this study, we evaluated the capacity of...
7.
Liu S, Chalouni C, Young J, Junttila T, Sliwkowski M, Lowe J
Cancer Immunol Res
. 2014 Nov;
3(2):173-83.
PMID: 25387893
Antibody-dependent cellular cytotoxicity (ADCC) is a key mechanism by which therapeutic antibodies mediate their antitumor effects. The absence of fucose on the heavy chain of the antibody increases the affinity...
8.
Uppal H, Doudement E, Mahapatra K, Darbonne W, Bumbaca D, Shen B, et al.
Clin Cancer Res
. 2014 Nov;
21(1):123-33.
PMID: 25370470
Purpose: Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) comprising the cytotoxic agent DM1 conjugated to trastuzumab with a stable linker. Thrombocytopenia was the dose-limiting toxicity in the phase I study,...
9.
Pillow T, Tien J, Parsons-Reponte K, Bhakta S, Li H, Staben L, et al.
J Med Chem
. 2014 Sep;
57(19):7890-9.
PMID: 25191794
Antibody-drug conjugates (ADCs) have a significant impact toward the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuzumab...
10.
Vu T, Sliwkowski M, Claret F
Biochim Biophys Acta
. 2014 Jul;
1846(2):353-65.
PMID: 25065528
HER2-positive (HER2+) breast cancer accounts for 18%-20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted...